Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company...
2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...
2024-04-11 22:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 fina...
A look at the top 10 most actives in the United States Auddia Inc. (AUUD) rose 147.6% to $3.54 on volume of 159,627,983 shares Beneficient (BENF) rose 61.2% to $0.083 on volume of 129,486,507 shares Tesla Inc. (TSLA) rose 4.9% to $172.98 on volume of 103,974,146 shares Selina Hospitalit...
2024-04-03 12:35:07 ET More on Glaukos Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript Glaukos: Remains A Hold Due To High Valuation And Negative Profitability Glaukos Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Glaukos ...
New J-code for iDose TR ® , J7355, set to become effective July 1, 2024 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announce...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract an...
2024-03-22 23:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-17 19:46:57 ET More on the markets SPTM: A Solid But Unnecessary Total Market ETF S&P 500: Time To Hedge, Here's How How the Magnificent 7 valuations stack up against bubbles of yore S&P 500 notches two-week losing streak ahead of key Fed rate...
News, Short Squeeze, Breakout and More Instantly...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company...
2024-04-11 22:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 fina...